Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.01 per share
-
Shares outstanding
-
46.2M
-
Number of holders
-
158
-
Total 13F shares, excl. options
-
43.9M
-
Shares change
-
+3.97M
-
Total reported value, excl. options
-
$877M
-
Value change
-
+$94.3M
-
Put/Call ratio
-
0.27
-
Number of buys
-
81
-
Number of sells
-
-67
-
Price
-
$19.95
Significant Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q3 2025
197 filings reported holding URGN - UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share as of Q3 2025.
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) has 158 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 43.9M shares
of 46.2M outstanding shares and own 94.95% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (4.54M shares), Paradigm Biocapital Advisors LP (4.22M shares), TORONTO DOMINION BANK (3.19M shares), BlackRock, Inc. (2.58M shares), MORGAN STANLEY (2.53M shares), Jefferies Financial Group Inc. (2.2M shares), SILVERARC CAPITAL MANAGEMENT, LLC (1.58M shares), MILLENNIUM MANAGEMENT LLC (1.47M shares), ACORN CAPITAL ADVISORS, LLC (1.26M shares), and SG Americas Securities, LLC (1.16M shares).
This table shows the top 158 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.